ALNYLAM PHARMACEUTICALS, INC. Deferred Foreign Income Tax Expense (Benefit)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Deferred Foreign Income Tax Expense (Benefit) of -$2.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2025 was -$2.20M.
- ALNYLAM PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2024 was -$106.76M.
- ALNYLAM PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2023 was -$713.00K.
- ALNYLAM PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2022 was -$1.43M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$2.20M 10-K · filed 2026-02-12 |
| 2024-12-31 | -$106.76M 10-K · filed 2026-02-12 |
| 2023-12-31 | -$713.00K 10-K · filed 2026-02-12 |
| 2022-12-31 | -$1.43M 10-K · filed 2025-02-13 |
| 2021-12-31 | -$2.77M 10-K · filed 2024-02-15 |
| 2020-12-31 | -$3.61M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$2.37M 10-K · filed 2022-02-10 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
| 2013-12-31 | -$34.00K 10-K · filed 2016-02-12 |
| 2012-12-31 | -$52.00K 10-K · filed 2015-02-13 |
| 2011-12-31 | -$52.00K 10-K · filed 2014-02-20 |
| 2010-12-31 | -$52.00K 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |